STUDY TITLE: A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

NCT07136077

This is a Phase 2 study to determine if a combination of fruquintinib and tislelizumab can control CRC in patients who have received treatment for the disease but still have “positive” ctDNA tests for MRD.

Status: Not yet Recruiting

Key Eligibility Criteria

  • Patients with confirmed microsatellite stable (MSS) stage II-IV colon adenocarcinoma
  • Patients must:
    • have completed curative intent treatments that must include 3 or more months of oxaliplatin containing chemotherapy
    • have no radiographic evidence of disease within 28 days of a positive ctDNA assay
    • have ctDNA positive assay

 

Treatment

Drug: Telisotuzumab, a PD-1 inhibitor

Drug: Fruquintinib, a VEGFR inhibitor

Study Plan